APA (7th ed.) Citation

Maréchal, C., Lal, H., Heineman, T. C., Poder, A., Ferguson, M., Enweonye, I., . . . Talli, J. (2018). Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial. Vaccine, 36(29), 4278. https://doi.org/10.1016/j.vaccine.2018.05.110

Chicago Style (17th ed.) Citation

Maréchal, Céline, et al. "Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine Co-administered with the 23-valent Pneumococcal Polysaccharide Vaccine in Adults ≥50 years of Age: A Randomized Trial." Vaccine 36, no. 29 (2018): 4278. https://doi.org/10.1016/j.vaccine.2018.05.110.

MLA (9th ed.) Citation

Maréchal, Céline, et al. "Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine Co-administered with the 23-valent Pneumococcal Polysaccharide Vaccine in Adults ≥50 years of Age: A Randomized Trial." Vaccine, vol. 36, no. 29, 2018, p. 4278, https://doi.org/10.1016/j.vaccine.2018.05.110.